National Planning Corp cut its position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 62.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,600 shares of the biopharmaceutical company’s stock after selling 31,150 shares during the period. National Planning Corp’s holdings in Cara Therapeutics were worth $306,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC purchased a new position in Cara Therapeutics during the fourth quarter worth about $845,000. Private Advisor Group LLC raised its stake in Cara Therapeutics by 120.5% in the first quarter. Private Advisor Group LLC now owns 23,737 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 12,970 shares in the last quarter. KCG Holdings Inc. bought a new stake in Cara Therapeutics during the first quarter valued at about $673,000. Creative Planning raised its stake in Cara Therapeutics by 9.3% in the first quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,215 shares in the last quarter. Finally, State Street Corp raised its stake in Cara Therapeutics by 7.1% in the fourth quarter. State Street Corp now owns 348,531 shares of the biopharmaceutical company’s stock valued at $3,244,000 after buying an additional 23,222 shares in the last quarter. Institutional investors and hedge funds own 51.58% of the company’s stock.
Cara Therapeutics, Inc. (NASDAQ:CARA) opened at 14.27 on Tuesday. The stock’s 50 day moving average is $15.80 and its 200-day moving average is $16.45. The company’s market capitalization is $464.93 million. Cara Therapeutics, Inc. has a 12-month low of $5.27 and a 12-month high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.32. During the same quarter last year, the company earned ($0.48) earnings per share. The firm’s quarterly revenue was down 100.0% on a year-over-year basis. On average, equities analysts predict that Cara Therapeutics, Inc. will post ($1.78) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/08/15/cara-therapeutics-inc-cara-shares-sold-by-national-planning-corp.html.
Several research firms have issued reports on CARA. Vetr upgraded shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $27.58 price target on the stock in a research report on Wednesday, June 28th. Janney Montgomery Scott restated a “buy” rating and issued a $22.00 price target on shares of Cara Therapeutics in a research report on Wednesday, June 28th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price target (down from $24.00) on shares of Cara Therapeutics in a research report on Friday, June 30th. Laidlaw decreased their price target on shares of Cara Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, June 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research report on Wednesday, June 21st. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Cara Therapeutics currently has an average rating of “Buy” and an average target price of $25.18.
In related news, Director Dean Slagel sold 250,000 shares of the company’s stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $25.87, for a total value of $6,467,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the company’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $15.00, for a total transaction of $45,000.00. Following the completion of the transaction, the vice president now owns 120,000 shares in the company, valued at $1,800,000. The disclosure for this sale can be found here. Insiders sold 278,000 shares of company stock worth $6,888,750 over the last 90 days. 7.50% of the stock is currently owned by corporate insiders.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Want to see what other hedge funds are holding CARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cara Therapeutics, Inc. (NASDAQ:CARA).
What are top analysts saying about Cara Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc. and related companies.